团队结合年龄与p-tau217水平，构建出一个模型。该模型可预估发病时间，误差控制在3—4年间。 该法提供的可量化生物标志物，将大幅降低临床试验的门槛与成本。精准预测发病与否及时机，有助于 设计预防或延缓病情的干预方案。 下一步，团队计划纳入更多的相关蛋白指标，以缩小误差。此外，还需更多样化样本的研究以确证结 果。 （文章来源：科技日报） 美国华盛顿大学医学院研究团队开发出一种便捷的血检方法。该方法不仅有望预估个体罹患阿尔茨海默 病的风险，更能推演发病的时间。相关论文发表于最新一期《自然·医学》杂志。 该方法聚焦于检测一种异常Tau蛋白。该蛋白在患者出现记忆丧失等症状前，便已在大脑积聚。团队表 示，若经大规模研究确证，这种方法将为神经退行性疾病的早期干预提供契机。 异常Tau蛋白会形成纤维缠结，阻碍神经信号传递。既往诊断常依赖脑成像检测这些缠结，虽能预测症 状出现时间，但技术繁冗且昂贵。团队致力于探索更简易的血液检测，以追踪Tau蛋白踪迹。 为此，团队分析了两项大型研究中600名老者的血液与认知数据，锁定了一种名为p-tau217的异常蛋 白。他们发现，早在认知症状出现前，血液中p-tau217与正常Tau蛋 ...

Key Takeaways MYGN reported Q4 adjusted EPS of 4 cents, beating estimates by 350% as shares surged 21.7% after hours.MYGN's revenues of $209.8M topped estimates, driven by gains in cancer and tumor profiling tests.MYGN's gross margin fell to 70%, while 2026 revenue guidance stands at $860M-$880M.Myriad Genetics, Inc. (MYGN) reported fourth-quarter 2025 adjusted earnings of 4 cents per share, which surpassed the Zacks Consensus Estimate by 350% and increased 33.3% year over year. Adjusted earnings exclude am ...

本报讯 记者徐婕报道 近日，国家卫生健康委临床检验中心颁布2025年室间质量评价证书，昆明市延安 医院精准医学中心参加的22个项目均顺利通过评估并获得证书，体现了中心在分子诊断检测能力、数据 分析与报告解读能力、质量控制体系建设等方面达到国家评价标准。 国家卫生健康委临床检验中心作为国家级临床检验质量管理与控制机构，其组织开展的室间质量评价是 国内临床检验领域极具权威性的质量评估。该评价通过向各参评实验室发放同一批次样本，明确检测标 准并收集回报结果，再进行统计学比对与综合研判，以此客观精准评估实验室的检测准确性、校准溯源 能力及持续质量监控水平，进而推动实验室不断完善质量体系、提升服务能力。 市延安医院精准医学中心通过评估的22个项目涵盖三大核心方向。肿瘤精准用药相关检测，能精准找到 肿瘤治疗的关键"靶点"，为癌症患者制定个性化用药方案提供依据；产前筛查与诊断，包括常见唐氏综 合征、爱德华氏综合征、帕陶氏综合征等胎儿染色体异常筛查，以及胎儿染色体核型分析，为备孕家庭 和新生儿健康保驾护航；遗传病及复杂变异检测，像地中海贫血分型、特定遗传病基因异常等检测，能 帮助确诊遗传性疾病，为后续诊疗和遗传咨询提供支持。 ...

Core Viewpoint - Mediterranean anemia is a common hereditary blood disorder that affects red blood cell production, leading to anemia symptoms. Early screening and preventive measures can significantly reduce the risk of children inheriting the disease from parents [1]. Group 1: What is Mediterranean Anemia? - Mediterranean anemia is caused by genetic mutations and is classified into two types: α-thalassemia and β-thalassemia. It affects hemoglobin synthesis, resulting in symptoms such as anemia, fatigue, and decreased immunity [2]. - α-thalassemia is due to the deletion or mutation of the α-chain gene, leading to varying degrees of anemia and potential complications like liver and spleen enlargement [2]. - β-thalassemia results from defects in the β-chain gene, causing severe anemia and symptoms like jaundice and skeletal deformities [2]. Group 2: Genetic Inheritance of Mediterranean Anemia - Mediterranean anemia follows an autosomal recessive inheritance pattern, meaning that both parents must carry the gene for their child to be affected. If only one parent is a carrier, the child is typically healthy but may be a carrier [3][4]. Group 3: Symptoms and Hazards of Mediterranean Anemia - Common symptoms include fatigue, dizziness, and pallor [5]. - Patients may experience liver and spleen enlargement, which can impair organ function [6]. - Severe cases, particularly of β-thalassemia, may lead to skeletal deformities and short stature [7]. - Long-term anemia can weaken the immune system, increasing susceptibility to infections [8]. Group 4: Importance of Prenatal Prevention - Prenatal prevention is crucial as it allows parents to determine if they are carriers of the Mediterranean anemia gene through screening. This knowledge enables them to take measures to reduce the risk of having an affected child [9]. Group 5: Recommended Prenatal Checks - Genetic screening for Mediterranean anemia is essential to identify if either parent is a carrier. This typically includes tests for both α and β-thalassemia genes [10][11]. - A complete blood count can help detect anemia, although carriers may not show obvious symptoms [11]. - Iron level testing is important to rule out iron deficiency anemia, which can exacerbate symptoms [11]. - A comprehensive health assessment for both parents is recommended to ensure overall health before pregnancy [11]. Group 6: Preventing the Birth of Affected Children - Couples can reduce the risk of having a child with Mediterranean anemia through genetic screening and counseling. If both parents are carriers, they may consider pre-implantation genetic diagnosis [12]. - Choosing a partner who is not a carrier can significantly lower the chances of having an affected child [12]. - Early detection and intervention during pregnancy, such as amniocentesis or non-invasive DNA testing, are crucial if there is a risk of the fetus having the condition [12]. Conclusion - Mediterranean anemia, as a hereditary disease, can be effectively prevented through prenatal genetic screening and early intervention. Understanding genetic carrier status and taking necessary precautions can greatly reduce the risk of having an affected child, emphasizing the importance of prenatal checks for prospective parents [13].

证券日报网讯1月29日，兰卫医学（301060）在互动平台回答投资者提问时表示，公司提供的检测服务 涵盖分子检验、生化检验、免疫检验、微生物检测、临床基础检验(临床体液与血液检测)等门类。 ...

接连获得两国极具分量的行业标杆客户，反映出觅瑞在胃癌早筛领域的技术实力得到市场认可。对此， 今日公司股价收涨7.77%，其估值及成长价值正受到市场关注。 胃癌早筛龙头觅瑞（Mirxes）今日股价强势上涨7.77%，市场表现亮眼。其背后核心驱动在于公司近期 接连获得泰国与中国市场顶级战略客户，商业化突破获得关键验证。 具体而言，在国内市场，觅瑞与大型央企——中铁物贸集团达成合作，为其员工群体提供胃癌早筛服 务。此举标志着公司创新产品成功切入国内大型企业健康管理市场，具备重要示范意义。 在海外拓展上，公司也取得显著的里程碑式进展——与泰国最大医疗集团BDMS旗下高端品牌N Health 建立战略伙伴关系。双方将共同推动胃癌早筛在泰国高端市场的应用。BDMS在东南亚地区拥有广泛影 响力，此合作被视为觅瑞产品国际化商业落地的重要突破口。 ...

Core Viewpoint - GIC Private Limited has increased its stake in Adicon Holdings (09860), acquiring 891,500 shares at HKD 5 per share, totaling HKD 4.4575 million, bringing its total holdings to 36.8375 million shares, representing 5.07% ownership, triggering a mandatory disclosure [1] Group 1: Company Developments - Adicon's strategic focus on AI in medical testing has garnered significant market attention, transitioning from traditional models to intelligent and ecological approaches [1] - The company signed a cooperation agreement with Huawei Cloud in December, marking the beginning of a new chapter in smart healthcare powered by AI technology [1] - Adicon announced plans to acquire Crown Bioscience for up to USD 204 million by November 2025, which will enhance its capabilities in drug development and diagnostics [1] Group 2: Market Reactions - Jefferies has issued a "Buy" rating for Adicon Holdings with a target price of HKD 12.60, citing the company's strategic moves in AI medical testing and the acquisition of Crown Bioscience as key factors [2] - Analysts suggest that GIC's stake increase may create a demonstration effect, promoting Adicon's ecological expansion in the AI medical sector and solidifying its position as a leading quality asset in the industry [2]

Group 1 - GIC Private Limited increased its stake in Adicon Holdings (09860) by purchasing 891,500 shares at HKD 5 per share, totaling HKD 4.4575 million, bringing its total holdings to 36.8375 million shares, representing 5.07% of the company, officially triggering the takeover threshold [1] - Adicon's strategic focus on AI in medical testing has garnered significant market attention, as the company transitions its medical testing services from traditional models to intelligent and ecological approaches [1] - In December 2022, Adicon signed a cooperation agreement with Huawei Cloud to initiate a new chapter in smart healthcare powered by AI technology, showcasing its technological iteration path and forward-looking layout in AI medical innovation applications [1] Group 2 - Adicon announced plans to acquire Crown Bioscience for up to USD 204 million, which is expected to significantly enhance the company's comprehensive strength in the drug development and diagnostic value chain [1] - Jefferies Financial has issued a "Buy" rating for Adicon Holdings (09860) with a target price of HKD 12.60, citing the company's strategic layout in AI medical testing and the acquisition of Crown Bioscience as major initiatives to strengthen its position [2] - Analysts suggest that GIC's stake increase may create a demonstration effect, promoting Adicon's ecological expansion in the AI medical field and further solidifying its market position as a leading quality asset in the industry [2]

Core Viewpoint - Huajian Medical's stock price increased by 16.88% following the announcement of a new detection solution for Nipah virus, indicating positive market response to the company's advancements in medical technology [1][3]. Group 1: Company Developments - On January 27, Huajian Medical announced that its subsidiary, Shenzhen Carbonhua Biotechnology Co., Ltd., successfully developed a dual-platform detection solution for Nipah virus, capable of comprehensive technical support from rapid screening to precise tracing [3]. - The intelligent fluorescence PCR rapid detection platform utilizes machine learning algorithms and a self-constructed species-specific nucleic acid database to efficiently identify and lock onto conserved gene regions of high-risk pathogens like Nipah virus, enabling rapid and accurate primer design and system optimization [3]. - The high-throughput sequencing and intelligent analysis platform relies on a continuously updated multi-species pathogen genome database, covering 18,628 types of pathogens, allowing for simultaneous detection and differentiation of Nipah virus and other coexisting pathogens [3]. - Huajian Medical emphasized that the rapid implementation of Nipah virus detection capabilities reflects the technological strength of Carbonhua Biotechnology and is a significant part of the company's overall AI medical strategy [3]. - The company is accelerating the construction of a next-generation public health prevention and control paradigm, integrating "AI early warning + rapid diagnosis + ecological collaboration," as it progresses with the acquisition of Chuangye Huikang [3].

Group 1 - The Hang Seng Index rose by 2.21%, gaining 598 points to close at 27,725 points, while the Hang Seng Tech Index increased by 1.74% [1] - Kuaishou-W (01024) saw a more than 3% increase, with UBS raising its target price to HKD 108 due to strong early-year performance in commercialization [1] - Oil stocks collectively rose, with CNOOC (00883) leading blue chips with a 5.7% increase, driven by multiple factors pushing oil prices up [1] Group 2 - Semiconductor stocks performed strongly, with AI-driven price increases across the entire semiconductor supply chain; Naxin Micro (02676) rose by 10%, while other companies like Zhaoyi Innovation (03986) and Huahong Semiconductor (01347) also saw significant gains [1] - Gold stocks continued their recent upward trend, with international gold prices surpassing USD 5,200 and several central banks announcing increases in gold reserves; Zhaojin Mining (01818) rose over 5% [1] - Huajian Medical (01931) surged over 12% after its subsidiary successfully developed a dual-platform testing solution for Nipah virus [2] Group 3 - Xinyu Technology (01729) increased by 5%, benefiting from high demand in AI computing power construction, with its MPO and server businesses expected to be core beneficiaries [3] - WanGuo Gold Group (03939) rose over 7% as international gold prices reached new highs, with Morgan Stanley suggesting that the gold rally is not yet over [4] - CGN Mining (01164) saw a rise of over 9%, with company performance expected to benefit from rising uranium prices and improved pricing mechanisms [5] Group 4 - Xindong Company (02400) increased by over 6%, with its game "Xindong Town" gaining popularity overseas, surpassing 10 million downloads for the international version [6] - New stock Mingming Busy (01768) debuted with a significant increase of over 70% on its first day of trading [7] - Southern Manganese (01091) fell over 16% due to significant losses reported by its Tian Deng subsidiary and severe losses at its Zunyi company [8]